We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials
News

Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials

 Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials
News

Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " Pluristem Therapeutics Announces Interim Results from PLX-PAD Clinical Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pluristem Therapeutics Inc. has announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Data suggested that PLX-PAD is safe and potentially efficacious.

“We are encouraged by the consistency of the data and believe that PLX-PAD may be an effective treatment for CLI.”

Nine patients, representing one-third of the patients needed to complete the Phase I dose-escalating studies in the U.S. and Germany, have been dosed with PLX-PAD. Patients experienced no significant unfavorable effects related to PLX-PAD administration. Three of the nine patients dosed completed their three-month follow up and the data from those patients demonstrated a trend towards efficacy with a reduction in their Rutherford Category, a measure of the severity of their limb ischemia.

“The interim results are in line with the data from the first patient treated with PLX-PAD,” said Professor Doctor André Schmidt-Lucke, Director of the Franziskus-Krankenhaus Institute of Berlin, Germany. “We are encouraged by the consistency of the data and believe that PLX-PAD may be an effective treatment for CLI.”

Zami Aberman, chairman and CEO of Pluristem, added, “The interim results are a significant milestone for Pluristem as we advance in our Phase I clinical trials to further test the safety and potential efficacy of PLX-PAD.”
Advertisement